Beyond Patch and Pill: Gels, Sprays, and Rings
SaveBeyond the patch and pill, estrogen comes as gels, sprays, and rings. Gels and sprays are systemic, applied daily to ease hot flashes while bypassing the liver. A low-dose vaginal ring treats dryness locally with minimal absorption, and a higher-dose ring acts body-wide. The right form depends on your main symptom.
Last updated: July 2026
What forms of estrogen exist beyond the patch and pill?
Estrogen comes in several forms beyond the familiar patch and pill, and they fall into two broad groups: systemic and local. Systemic forms, including gels, sprays, and higher-dose rings, raise estrogen throughout the body and relieve hot flashes, night sweats, and bone loss, much like a patch 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.Consensus on systemic transdermal forms (gels, sprays, rings), their shared lower clot profile, and matching form to symptoms.2Ref 2MedlinePlus (National Library of Medicine) (2026).Hormone Replacement Therapy.Patient-facing overview of estrogen delivery forms including gels and sprays and their practical use.. Local forms, including low-dose vaginal creams, tablets, and a soft vaginal ring, act mainly on the vaginal and urinary tissues with minimal absorption into the bloodstream 3Ref 3Lethaby A, Ayeleke RO, Roberts H (2016).Local oestrogen for vaginal atrophy in postmenopausal women.Cochrane review finding local vaginal estrogen effectively relieves vaginal atrophy with few systemic effects..
According to menopause guidelines, matching the form to a woman's main symptom is the first step: whole-body symptoms point toward systemic estrogen, while vaginal dryness alone often points toward a local form 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.Consensus on systemic transdermal forms (gels, sprays, rings), their shared lower clot profile, and matching form to symptoms.3Ref 3Lethaby A, Ayeleke RO, Roberts H (2016).Local oestrogen for vaginal atrophy in postmenopausal women.Cochrane review finding local vaginal estrogen effectively relieves vaginal atrophy with few systemic effects.. Sorting the options into these two groups prevents a great deal of confusion.
How do gels and sprays work?
Gels and sprays deliver estradiol through the skin, similar to a patch but without an adhesive. A daily gel is rubbed onto the arm or thigh, and a spray is applied to the forearm, each drying within about 5 minutes 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.Consensus on systemic transdermal forms (gels, sprays, rings), their shared lower clot profile, and matching form to symptoms.2Ref 2MedlinePlus (National Library of Medicine) (2026).Hormone Replacement Therapy.Patient-facing overview of estrogen delivery forms including gels and sprays and their practical use.. Because the hormone crosses the skin and largely bypasses the liver, gels and sprays share the patch's lower clot-risk profile compared with oral estrogen 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.Consensus on systemic transdermal forms (gels, sprays, rings), their shared lower clot profile, and matching form to symptoms.4Ref 4National Institute for Health and Care Excellence (2026).Menopause: identification and management (NG23).2026 NICE guidance that transdermal routes are not linked to the increased clot risk seen with oral pills..
The main trade-off is taking care to let the area dry and to avoid skin-to-skin transfer to children or partners for a short window after applying 2Ref 2MedlinePlus (National Library of Medicine) (2026).Hormone Replacement Therapy.Patient-facing overview of estrogen delivery forms including gels and sprays and their practical use.. According to the 2026 NICE guideline, transdermal routes are not linked to the increased clot risk seen with pills 4Ref 4National Institute for Health and Care Excellence (2026).Menopause: identification and management (NG23).2026 NICE guidance that transdermal routes are not linked to the increased clot risk seen with oral pills.. For women who dislike patches or pills, a gel or spray offers the same relief with a different routine.
What does a vaginal ring do?
A vaginal ring comes in two very different strengths, which often causes confusion. A low-dose ring sits in the vagina, releases a small amount of estrogen locally, and eases dryness, irritation, and painful sex with minimal absorption into the bloodstream 3Ref 3Lethaby A, Ayeleke RO, Roberts H (2016).Local oestrogen for vaginal atrophy in postmenopausal women.Cochrane review finding local vaginal estrogen effectively relieves vaginal atrophy with few systemic effects.. It is typically replaced about every 90 days and does not, on its own, relieve hot flashes 3Ref 3Lethaby A, Ayeleke RO, Roberts H (2016).Local oestrogen for vaginal atrophy in postmenopausal women.Cochrane review finding local vaginal estrogen effectively relieves vaginal atrophy with few systemic effects..
A separate higher-dose systemic ring releases enough estrogen to act throughout the body, more like a patch 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.Consensus on systemic transdermal forms (gels, sprays, rings), their shared lower clot profile, and matching form to symptoms.. A Cochrane review found local vaginal estrogen effectively relieves atrophy symptoms with few systemic effects 3Ref 3Lethaby A, Ayeleke RO, Roberts H (2016).Local oestrogen for vaginal atrophy in postmenopausal women.Cochrane review finding local vaginal estrogen effectively relieves vaginal atrophy with few systemic effects.. Knowing which ring a clinician means matters, because the low-dose version carries a different risk profile than whole-body hormone therapy.
Who tends to choose each form?
Different forms tend to suit different women and life stages. Someone with a personal or family history of clots often leans toward a gel, spray, or patch over a pill for the lower clot risk 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.Consensus on systemic transdermal forms (gels, sprays, rings), their shared lower clot profile, and matching form to symptoms.4Ref 4National Institute for Health and Care Excellence (2026).Menopause: identification and management (NG23).2026 NICE guidance that transdermal routes are not linked to the increased clot risk seen with oral pills.. A woman whose only complaint is vaginal dryness or painful sex may do best with a local ring or cream rather than whole-body hormones 3Ref 3Lethaby A, Ayeleke RO, Roberts H (2016).Local oestrogen for vaginal atrophy in postmenopausal women.Cochrane review finding local vaginal estrogen effectively relieves vaginal atrophy with few systemic effects..
Across the transition, needs shift: a woman early in perimenopause with heavy night sweats may want systemic estrogen, while one more than 4 years past menopause with isolated dryness may want only a local form 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.Consensus on systemic transdermal forms (gels, sprays, rings), their shared lower clot profile, and matching form to symptoms.3Ref 3Lethaby A, Ayeleke RO, Roberts H (2016).Local oestrogen for vaginal atrophy in postmenopausal women.Cochrane review finding local vaginal estrogen effectively relieves vaginal atrophy with few systemic effects.. According to menopause guidelines, preference and consistency matter as much as pharmacology 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.Consensus on systemic transdermal forms (gels, sprays, rings), their shared lower clot profile, and matching form to symptoms.. Cost and daily routine round out the decision.
When the estrogen delivery choice needs a menopause clinician
A clinician who focuses on menopause can match one of these forms to your symptoms and health history. Your main complaint, whole-body symptoms versus vaginal dryness alone, along with your clot risk, skin tolerance, and preferences, guides whether a gel, spray, ring, patch, or pill fits best.
A gynecologist, menopause specialist, or primary care clinician can also compare a patch and pill against these options. Gale can help you prepare for that conversation. With more than half a dozen delivery methods available, most women can find a form that suits both their bodies and their routines.
Common questions
Related
Menopause & midlife
Estrogen Patch vs Pill: Choosing Your FormMenopause & midlife
HRT and High Blood Pressure: Usually CompatibleMenopause & midlife
Vaginal vs Systemic Estrogen: Local or Whole-Body
Say it back
How would you explain this to someone you love?
Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.
When to check in about your estrogen form
- —Swelling, warmth, or pain in one leg while using systemic estrogen can signal a clot and is a reason to seek urgent medical care.
- —Sudden shortness of breath or chest pain can signal a clot in the lung and is a reason to seek emergency care.
- —New or worsening pelvic pain or unusual discharge with a vaginal ring in place is a reason to arrange a clinician evaluation.
- —Unexplained vaginal bleeding after starting estrogen is a reason to arrange a gynecologic evaluation.
Sudden shortness of breath, chest pain, or one-sided leg swelling can signal a blood clot — call 911 or go to the nearest emergency room right away.
This article is general health education, not medical advice. Which estrogen form fits your symptoms and history is a decision to make with a gynecologist, menopause specialist, or primary care clinician.
References
- 1.The North American Menopause Society (Menopause Society) (2022). The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. doi:10.1097/GME.0000000000002028 ✓Consensus on systemic transdermal forms (gels, sprays, rings), their shared lower clot profile, and matching form to symptoms.
- 2.MedlinePlus (National Library of Medicine) (2026). Hormone Replacement Therapy. MedlinePlus, U.S. National Library of Medicine (NIH). link ✓Patient-facing overview of estrogen delivery forms including gels and sprays and their practical use.
- 3.Lethaby A, Ayeleke RO, Roberts H (2016). Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD001500.pub3 ✓Cochrane review finding local vaginal estrogen effectively relieves vaginal atrophy with few systemic effects.
- 4.National Institute for Health and Care Excellence (2026). Menopause: identification and management (NG23). National Institute for Health and Care Excellence (NICE). link ✓2026 NICE guidance that transdermal routes are not linked to the increased clot risk seen with oral pills.
4 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy